Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMTK3 | Q96Q04 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | PDK1 | Q15118 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 8/20 | 0.77 |
| ▸ | PRKCQ | Q04759 | 7/20 | 0.77 |
| ▸ | KDR | P35968 | 7/20 | 0.77 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.77 |
| ▸ | PRKCA | P17252 | 5/20 | 0.77 |
| ▸ | PRKCH | P24723 | 5/20 | 0.77 |
| ▸ | PRKCI | P41743 | 5/20 | 0.77 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.77 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.77 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.77 |
| ▸ | MAP3K11 | Q16584 | 5/20 | 0.77 |
| ▸ | PRKCG | P05129 | 4/20 | 0.77 |
| ▸ | PRKCB | P05771 | 4/20 | 0.77 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.77 |
| ▸ | MYLK | Q15746 | 4/20 | 0.77 |
| ▸ | MAP3K9 | P80192 | 4/20 | 0.77 |
| ▸ | MAP3K10 | Q02779 | 4/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394491 | 1.00 | LMTK3 (1.00) | LMTK3SMN1; SMN2PDK1NTRK1PRKCQ | |
| SCHEMBL24393927 | 1.00 | LMTK3 (1.00) | LMTK3SMN1; SMN2PDK1NTRK1PRKCQ | |
| SCHEMBL13169944 | 1.00 | LMTK3 (1.00) | LMTK3SMN1; SMN2PDK1NTRK1PRKCQ | |
| SCHEMBL5951557 | 1.00 | LMTK3 (1.00) | LMTK3SMN1; SMN2PDK1NTRK1PRKCQ | |
| SCHEMBL31119069 | 1.00 | LMTK3 (1.00) | LMTK3SMN1; SMN2PDK1NTRK1PRKCQ | |
| SCHEMBL23499574 | 0.88 | LMTK3 (0.78) | LMTK3SMN1; SMN2PDK1NTRK1PRKCQ | |
| K-252A SCHEMBL31181849 | 0.87 | NTRK1 (1.00) | LMTK3SMN1; SMN2PDK1NTRK1PRKCQ | |
| K-252A SCHEMBL24112155 | 0.87 | NTRK1 (1.00) | LMTK3SMN1; SMN2PDK1NTRK1PRKCQ | |
| K-252A SCHEMBL29660621 | 0.87 | NTRK1 (1.00) | LMTK3SMN1; SMN2PDK1NTRK1PRKCQ | |
| K-252A SCHEMBL32665760 | 0.87 | NTRK1 (1.00) | LMTK3SMN1; SMN2PDK1NTRK1PRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4512480-A2 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| EP-3082423-B1 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2024-12-11 | — | — | EP | claimed |
| EP-4389225-A2 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2024-06-26 | — | — | EP | claimed |
| EP-3082779-B1 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-116036278-A | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| EP-4062917-A1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2022-09-28 | — | — | EP | claimed |
| CN-110799245-B | Compositions and methods for treating cancer with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| EP-3082957-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-04-06 | — | — | EP | claimed |
| EP-3082957-A1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2016-10-26 | — | — | EP | claimed |
| WO-2015095838-A2 | CANCER TREATMENTS USING COMBINATIONS OF MEK TYPE I AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095829-A1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095842-A2 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095807-A1 | CANCER TREATMENTS USING COMBINATIONS OF EGFR AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095825-A1 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095834-A2 | CANCER TREATMENTS USING ERK1/2 AND BCL-2 FAMILY INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095831-A1 | CANCER TREATMENTS USING COMBINATIONS OF MTOR AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095840-A1 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2015095819-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2015-06-25 | — | — | WO | claimed |